Blog

NATCO living up to its purpose of “Making speciality medicines accessible to all” has launched generic brands of HEPCINAT (Sofosbuvir), HEPCINAT-LP (Ledipasvir/Sofosbuvir), NATDAC (Daclatasvir). NATCO is amongst the first companies to launch the generic versions of Sofusbuvir (SOF) and its combinations in India; this is truly a momentous occasion for the hepatitis C virus (HCV) care givers, patients and the company. With the affordable pricing of NATCO, therapy benefits would be accessible to all economic strata and even the semi-rural/rural areas of India. Eradication of HCV in India is a matter of time and is possible through concerted efforts and scaling up stringent preventive measures, screening, diagnosis & treatment.

SOF is a well-tolerated effective antiviral agent that is heralding a new era of all oral therapy for HCV. SOF is safe and can be used across different viral genotypes, disease stages, and special patient groups, such as those co-infected with human immunodeficiency virus. When used in combination with ribavirin or another direct-acting antiviral agent, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. More so than any other anti-HCV drug developed to date, SOF offers the widest applicability for all infected patients, and new regimens will be tailored to maximize performance. Sofosbuvir is truly an evolution and revolution in the treatment of HCV.

Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of Ledipasvir and 400 mg of sofosbuvir in a single tablet, It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.

HCV infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, Interferon and Ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects.

HEPCINAT and its combinations are available throughout India and dispensed against the prescription of a Hepatologist/Gastroenterologist/HCV treatment specialist.